Compare · HSKA vs NNNN
HSKA vs NNNN
Side-by-side comparison of Heska Corporation (HSKA) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSKA and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NNNN is the larger of the two at $3.31B, about 2.3x HSKA ($1.41B).
- NNNN has hit the wire 1 time in the past 4 weeks while HSKA has been quiet.
- HSKA has more recent analyst coverage (7 ratings vs 0 for NNNN).
- Company
- Heska Corporation
- Anbio Biotechnology
- Price
- $120.00+0.05%
- $18.23-34.52%
- Market cap
- $1.41B
- $3.31B
- 1M return
- -
- -30.41%
- 1Y return
- -
- +111.73%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2025
- News (4w)
- 0
- 1
- Recent ratings
- 7
- 0
Heska Corporation
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Additionally, the company provides a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Latest HSKA
- Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development
- SEC Form 15-12G filed by Heska Corporation
- SEC Form 4 filed by Maples Sharon J.
- SEC Form 4 filed by Eyl Steven M.
- SEC Form 4 filed by Hasenmaier Joachim A.
- SEC Form 4 filed by Davis Stephen L
- SEC Form 4 filed by Antin Robert L
- SEC Form 4 filed by Sveen David E.
- SEC Form 4 filed by Humphrey Scott
- SEC Form 4 filed by Furlong Mark F
Latest NNNN
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris
- SEC Form 3 filed by new insider Xu Cany
- SEC Form 20-F filed by Anbio Biotechnology
- Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum